View ValuationDarwin 향후 성장Future 기준 점검 5/6Darwin (는) 각각 연간 123% 및 27.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 121.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.4% 로 예상됩니다.핵심 정보123.0%이익 성장률121.85%EPS 성장률Biotechs 이익 성장23.5%매출 성장률27.1%향후 자기자본이익률7.40%애널리스트 커버리지Low마지막 업데이트21 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesDeclared Dividend • May 24Dividend of €0.56 announcedShareholders will receive a dividend of €0.56. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 9.8%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 392% over the next 2 years, which should provide support to the dividend and adequate earnings cover.공시 • May 23Darwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.공시 • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.New Risk • May 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$107.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (€92.4m market cap, or US$107.4m).Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €8.00, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 6.6% over the past three years.공시 • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €9.15, the stock trades at a forward P/E ratio of 33x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 21% over the past three years.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €9.75, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past three years.New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.65, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.Valuation Update With 7 Day Price Move • Oct 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €6.60, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 13% over the past three years.분석 기사 • Jul 06Darwin AG's (MUN:7V0) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 3.2x Darwin AG ( MUN:7V0 ) may be sending bullish signals at the moment...공시 • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.3m).공시 • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.이익 및 매출 성장 예측MUN:7V0 - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028137N/A-11N/A212/31/2027897-143212/31/2026590-17-3112/31/2025541-22-13N/A12/31/20242718-29-25N/A12/31/2023180-20-19N/A12/31/2022210459395N/A12/31/2021133231112N/A애널리스트 향후 성장 전망수입 대 저축률: 7V0 의 연간 예상 수익 증가율(123%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: 7V0 의 연간 수익(123%)이 German 시장(17.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 7V0 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: 7V0 의 수익(연간 27.1%)이 German 시장(연간 6.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 7V0 의 수익(연간 27.1%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 7V0의 자본 수익률은 3년 후 7.4%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 20:14종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Darwin AG는 2명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Cosmin FilkerGBC AGKlaus BreitenbachODDO BHF Corporate & Markets
Declared Dividend • May 24Dividend of €0.56 announcedShareholders will receive a dividend of €0.56. Ex-date: 29th June 2026 Payment date: 1st July 2026 Dividend yield will be 9.8%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The company is yet to establish a track record of dividend growth or stability as it hasn't paid a regular dividend for at least 2 years. EPS is expected to grow by 392% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
공시 • May 23Darwin AG announces Annual dividend, payable on July 01, 2026Darwin AG announced Annual dividend of EUR 0.5600 per share payable on July 01, 2026, ex-date on June 29, 2026 and record date on June 30, 2026.
공시 • May 22Darwin AG, Annual General Meeting, Jun 26, 2026Darwin AG, Annual General Meeting, Jun 26, 2026, at 13:30 W. Europe Standard Time.
New Risk • May 16New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$107.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (53% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (0.9% net profit margin). Market cap is less than US$100m (€92.4m market cap, or US$107.4m).
Reported Earnings • May 15Full year 2025 earnings released: EPS: €0.045 (vs €1.54 in FY 2024)Full year 2025 results: EPS: €0.045 (down from €1.54 in FY 2024). Revenue: €61.6m (up 125% from FY 2024). Net income: €545.5k (down 97% from FY 2024). Profit margin: 0.9% (down from 68% in FY 2024). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €8.00, the stock trades at a forward P/E ratio of 29x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 6.6% over the past three years.
공시 • Feb 26Darwin AG to Report Fiscal Year 2025 Results on May 12, 2026Darwin AG announced that they will report fiscal year 2025 results on May 12, 2026
Valuation Update With 7 Day Price Move • Feb 19Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to €9.15, the stock trades at a forward P/E ratio of 33x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 21% over the past three years.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment improves as stock rises 20%After last week's 20% share price gain to €9.75, the stock trades at a forward P/E ratio of 35x. Average trailing P/E is 18x in the Biotechs industry in Europe. Total returns to shareholders of 20% over the past three years.
New Risk • Jan 23New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 49% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 49% per year for the foreseeable future. Minor Risk Latest financial reports are more than 6 months old (reported December 2024 fiscal period end).
Valuation Update With 7 Day Price Move • Dec 18Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €7.65, the stock trades at a trailing P/E ratio of 5x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total loss to shareholders of 10% over the past three years.
Valuation Update With 7 Day Price Move • Oct 09Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to €6.60, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 19x in the Biotechs industry in Europe. Total loss to shareholders of 13% over the past three years.
분석 기사 • Jul 06Darwin AG's (MUN:7V0) Price Is Right But Growth Is LackingWith a price-to-sales (or "P/S") ratio of 3.2x Darwin AG ( MUN:7V0 ) may be sending bullish signals at the moment...
공시 • May 21+ 1 more updateDarwin AG, Annual General Meeting, Jun 27, 2025Darwin AG, Annual General Meeting, Jun 27, 2025, at 13:30 W. Europe Standard Time.
New Risk • Aug 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €84.6m (US$91.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid. Minor Risk Market cap is less than US$100m (€84.6m market cap, or US$91.3m).
공시 • May 14Darwin AG, Annual General Meeting, Jun 18, 2024Darwin AG, Annual General Meeting, Jun 18, 2024, at 11:00 W. Europe Standard Time.